Skip to main content Click to view our accessibility statement

Purpose of the TERPSIS Study

The TERPSIS Study is evaluating the safety and effectiveness of a once-weekly oral investigational medication on improving lack or loss of interest in usually pleasurable activities in participants with major depressive disorder (MDD).

Terpsis Study logo

Who May Qualify

Eligible participants must:

  • Be 18 to 65 years of age (inclusive)
  • Have a confirmed diagnosis of MDD
  • Be currently on antidepressant medication(s)
  • Not be pregnant or breastfeeding
  • Not have a current psychiatric disorder other than MDD

Additional eligibility criteria apply, which will be discussed with potential participants.

See if you may qualify

Study Participation

The total length of the TERPSIS Study is approximately 20 weeks. This includes a 4-week screening period to make sure the research study is a good match for you, an 8-week treatment period in which you will receive either the investigational medication or placebo, and an 8-week follow-up period to check on your health after stopping the assigned study treatment. Participants in the TERPSIS Study will be able to stay on their current antidepressant medication(s) while in the study.

Throughout the research study, your study doctor may perform a number of tests and procedures, including but not limited to:

  • Recording your medical history
  • Conducting a physical exam
  • Measuring your vital signs
  • Conducting a pregnancy test (if applicable)
  • Collecting blood and urine samples

Purpose of the SAVITRI Study

The SAVITRI Study is evaluating the safety and effectiveness of a once-daily oral investigational medication on improving symptoms of MDD in patients who are having an inadequate response to antidepressant medication(s).

Savitri Study logo

Who May Qualify

Eligible participants must:

  • Be 18 to 65 years of age (inclusive)
  • Have a confirmed diagnosis of MDD
  • Be currently on antidepressant medication(s)
  • Have had inadequate response to up to 5 oral antidepressant medications
  • Not be pregnant or breastfeeding
  • Not have a current psychiatric disorder other than MDD

Additional eligibility criteria apply, which will be discussed with potential participants.

See if you may qualify

Study Participation

The total length of the SAVITRI Study is approximately 14 weeks. This includes a 4-week screening period to make sure the research study is a good match for you, an 8-week treatment period in which you will receive 1 of 2 doses of the investigational medication or the placebo, and a 2-week follow-up period to check on your health after stopping the assigned study treatment. Participants in the SAVITRI Study will be able to stay on their current antidepressant medication(s) while in the research study.

Throughout the research study, your study doctor may perform a number of tests and procedures, including but not limited to:

  • Recording your medical history
  • Conducting a physical exam
  • Measuring your vital signs
  • Conducting a pregnancy test (if applicable)
  • Collecting blood and urine samples